about
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first ...
Read More
288.23
3.53
(1.24%)
1.8M
XNAS Volume
XNAS 08 Aug, 2025 5:30 PM (EDT)
High Financial Strength
Mid Valuation
Technically Neutral
Mid-range Performer
These stocks are with strong quality. Their reasonable financials and technical aspects successfully gather investor's interest.
View Similar
Embed DVM
Amgen Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..